

A PHASE III TRIAL OF ONE VS. TWO YEARS OF MAINTENANCE OLAPARIB, WITH OR WITHOUT BEVACIZUMAB, IN PATIENTS WITH BRCA1/2 MUTATED OR HOMOLOGOUS RECOMBINATION DEFICIENT (HRD+) OVARIAN CANCER FOLLOWING RESPONSE TO FIRST LINE PLATINUM-BASED CHEMOTHERAPY

Status: Recruiting

Eligibility Criteria

Sex: Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- newly diagnosed, confirmed stage III or IV ovarian cancer of the following types: high grade serous or endometrioid, or other epithelial ovarian cancer with BRCA1/2 alteration - ovarian cancer includes ovarian, fallopian, or primary peritoneal cancer - must have had cytoreductive surgery - must have completed first line platinum-based therapy before starting the study (no more than 12 weeks prior) - not pregnant or breastfeeding - see link to clinicaltrials.gov for complete inclusion criteria

Conditions & Interventions

Conditions:

Cancer

Keywords:

Fallopian Tube Cancer, Ovarian Cancer, Clinics and Surgery Center (CSC)

More Information

Description: The usual approach for patients who are not in a study is treatment of ovarian cancer with surgery, radiation, or U.S. Food and Drug Administration (FDA)-approved drugs. Sometimes, combinations of these treatments are used. We are doing this study because we want to find out if the use of Olaparib for one year is as good or worse than the usual approach for ovarian tumor.

Study Contact: Erin Zielinski - eezielin@umn.edu

Principal Investigator: Jordan N Mattson

Phase: PHASE3

IRB Number: STUDY00024824

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.